World's Best Scientists 2026 revealed!

D-Index & Metrics

Biology and Biochemistry

D-Index
108
Citations
42718
World Ranking
1045
National Ranking
632

Overview

Joel Linden is affiliated with the University of Virginia in the United States and has contributed extensively to the fields of Biochemistry, Genetics and Molecular Biology, and Medicine. Their research spans several subfields, including Physiology, Molecular Biology, Surgery, Immunology, and Infectious Diseases.

Their work prominently focuses on key topics such as Adenosine and Purinergic Signaling, Immune Cell Function and Interaction, Pharmacological Receptor Mechanisms and Effects, Transplantation Methods and Outcomes, COVID-19 Clinical Research Studies, Organ Transplantation Techniques and Outcomes, and Receptor Mechanisms and Signaling.

Joel Linden has coauthored multiple publications with frequent collaborators including Preeti Chhabra, Kenneth L. Brayman, Christine L. Lau, Yunge Zhao, and Mark R. Conaway.

Their research has appeared in various publication venues, with recurring publications in the IUPHAR/BPS Guide to Pharmacology CITE, bioRxiv (Cold Spring Harbor Laboratory), Immunity, Cancer Immunology Research, and the Journal of Allergy and Clinical Immunology.

Notable recent papers include:

  • Sepsis expands a CD39+ plasmablast population that promotes immunosuppression via adenosine-mediated inhibition of macrophage antimicrobial activity, 2021, Immunity
  • The Expression of Adenosine A2B Receptor on Antigen-Presenting Cells Suppresses CD8+ T-cell Responses and Promotes Tumor Growth, 2020, Cancer Immunology Research
  • Clearance of apoptotic cells by lung alveolar macrophages prevents development of house dust mite-induced asthmatic lung inflammation, 2020, Journal of Allergy and Clinical Immunology
  • Cellular sensing of extracellular purine nucleosides triggers an innate IFN-β response, 2020, Science Advances
  • Targeting Adenosine with Adenosine Deaminase 2 to Inhibit Growth of Solid Tumors, 2021, Cancer Research

Best Publications

  • International Union of Pharmacology. XXV. Nomenclature and Classification of Adenosine Receptors

    Bertil B. Fredholm;Adriaan P. IJzerman;Kenneth A. Jacobson;Karl-Norbert Klotz

  • Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression

    Silvia Deaglio;Karen M. Dwyer;Wenda Gao;David J Friedman

  • International Union of Basic and Clinical Pharmacology. LXXXI. Nomenclature and Classification of Adenosine Receptors—An Update

    Bertil B. Fredholm;Adriaan P. IJzerman;Kenneth A. Jacobson;Joel Linden

  • Adenosine receptors: therapeutic aspects for inflammatory and immune diseases

    György Haskó;Joel Linden;Bruce Cronstein;Pál Pacher

  • The cardiac effects of adenosine

    Luiz Belardinelli;Luiz Belardinelli;Joel Linden;Joel Linden;Robert M. Berne;Robert M. Berne

  • Molecular Approach to Adenosine Receptors: Receptor-Mediated Mechanisms of Tissue Protection

    J Linden

  • Purinergic regulation of the immune system

    Caglar Cekic;Joel Linden

  • A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells

    Paul E. Zarek;Ching Tai Huang;Eric R. Lutz;Jeanne Kowalski

  • Molecular cloning and characterization of the human A3 adenosine receptor

    Christopher A. Salvatore;Marlene A. Jacobson;Heidi E. Taylor;Joel Linden

  • Cloned adenosine A3 receptors: pharmacological properties, species differences and receptor functions.

    Joel Linden

  • Immunohistochemical localization of adenosine A2A receptors in the rat central nervous system.

    Diane L. Rosin;Anna Robeva;Robin L. Woodard;Patrice G. Guyenet

  • A2A adenosine receptor induction inhibits IFN-gamma production in murine CD4+ T cells.

    Courtney M. Lappas;Jayson M. Rieger;Joel Linden

  • Renal ischemia-reperfusion injury and adenosine 2A receptor-mediated tissue protection: role of macrophages

    Yuan-Ji Day;Liping Huang;Hong Ye;Joel Linden

  • The role of inflammation in vascular diseases.

    Gail W. Sullivan;Ian J. Sarembock;Joel Linden

  • Myocardial infarct-sparing effect of adenosine A2A receptor activation is due to its action on CD4+ T lymphocytes.

    Zequan Yang;Yuan-Ji Day;Marie-Claire Toufektsian;Yaqin Xu

  • Renal protection from ischemia mediated by A2A adenosine receptors on bone marrow–derived cells

    Yuan-Ji Day;Liping Huang;Marcia J. McDuffie;Diane L. Rosin

  • Adenosine A2A receptor activation reduces hepatic ischemia reperfusion injury by inhibiting CD1d-dependent NKT cell activation

    Courtney M. Lappas;Yuan-Ji Day;Melissa A. Marshall;Victor H. Engelhard

  • Adenosine in tissue protection and tissue regeneration.

    Joel Linden

  • Molecular cloning and functional expression of a sheep A3 adenosine receptor with widespread tissue distribution.

    J Linden;H E Taylor;A S Robeva;A L Tucker

  • Structure and function of A1 adenosine receptors.

    Joel Linden

Frequent Co-Authors

Irving L. Kron
Irving L. Kron University of Virginia
Timothy L. Macdonald
Timothy L. Macdonald University of Virginia
David G. Nathan
David G. Nathan Harvard University
Peter J. Scammells
Peter J. Scammells Monash University
Peter B. Ernst
Peter B. Ernst University of California, San Diego
Kenneth A. Jacobson
Kenneth A. Jacobson National Institutes of Health
George A. Beller
George A. Beller University of Virginia
Jiang-Fan Chen
Jiang-Fan Chen Boston University
Donna Neuberg
Donna Neuberg Harvard University
Richard L. Guerrant
Richard L. Guerrant University of Virginia

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Best Scientists Citing Joel Linden

Trending Scientists